Hostname: page-component-77f85d65b8-5ngxj Total loading time: 0 Render date: 2026-03-29T16:48:09.600Z Has data issue: false hasContentIssue false

Session 4: CVD, diabetes and cancer Evidence for the use of the Mediterranean diet in patients with CHD

Symposium on ‘Dietary management of disease’

Published online by Cambridge University Press:  15 December 2009

Pascal P. McKeown*
Affiliation:
Centre for Public Health, Institute of Clinical Science B, Queen's University Belfast, Grosvenor Road, Belfast BT12 6BJ, UK
Karen Logan
Affiliation:
Centre for Public Health, Institute of Clinical Science B, Queen's University Belfast, Grosvenor Road, Belfast BT12 6BJ, UK
Michelle C. McKinley
Affiliation:
Centre for Public Health, Institute of Clinical Science B, Queen's University Belfast, Grosvenor Road, Belfast BT12 6BJ, UK
Ian S. Young
Affiliation:
Centre for Public Health, Institute of Clinical Science B, Queen's University Belfast, Grosvenor Road, Belfast BT12 6BJ, UK
Jayne V. Woodside
Affiliation:
Centre for Public Health, Institute of Clinical Science B, Queen's University Belfast, Grosvenor Road, Belfast BT12 6BJ, UK
*
*Corresponding author: Dr Pascal McKeown, fax +44 28 90329899, email p.p.mckeown@qub.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Diet is associated with the development of CHD. The incidence of CHD is lower in southern European countries than in northern European countries and it has been proposed that this difference may be a result of diet. The traditional Mediterranean diet emphasises a high intake of fruits, vegetables, bread, other forms of cereals, potatoes, beans, nuts and seeds. It includes olive oil as a major fat source and dairy products, fish and poultry are consumed in low to moderate amounts. Many observational studies have shown that the Mediterranean diet is associated with reduced risk of CHD, and this result has been confirmed by meta-analysis, while a single randomised controlled trial, the Lyon Diet Heart study, has shown a reduction in CHD risk in subjects following the Mediterranean diet in the secondary prevention setting. However, it is uncertain whether the benefits of the Mediterranean diet are transferable to other non-Mediterranean populations and whether the effects of the Mediterranean diet will still be feasible in light of the changes in pharmacological therapy seen in patients with CHD since the Lyon Diet Heart study was conducted. Further randomised controlled trials are required and if the risk-reducing effect is confirmed then the best methods to effectively deliver this public health message worldwide need to be considered.

Information

Type
Research Article
Copyright
Copyright © The Authors 2009
Figure 0

Fig. 1. Simplified schema of diversity of lesions in human coronary atherosclerosis. This schematic depicts two morphological extremes of coronary atherosclerotic plaques. Stenotic lesions tend to have: smaller lipid cores, more fibrosis and calcification; thick fibrous caps; less compensatory enlargement (positive remodelling) Non-stenotic lesions generally outnumber stenotic plaques and tend to have large lipid cores and thin fibrous caps susceptible to rupture and thrombosis. They often undergo substantial compensatory enlargement that leads to underestimation of lesion size by angiography. Non-stenotic plaques may cause no symptoms for many years but when disrupted can provoke an episode of unstable angina or myocardial infarction. Enlarged segments of the schematic show longitudinal section (left) and cross section (right) Many coronary atherosclerotic lesions may lie between these two extremes, produce mixed clinical manifestations and require multipronged management. PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft. (From Libby & Theroux(6); reproduced with permission.)

Figure 1

Fig. 2. Key features of the Mediterranean diet expressed as a Mediterranean diet pyramid. (From Oldways Preservation & Exchange Trust(149); reproduced with permission.)

Figure 2

Fig. 3. Risk of mortality from CVD associated with two-point increase in adherence score for Mediterranean diet. (▪), Effect size and 95% CI represented by horizontal lines; (◆), total effect size. (From Sofi et al.(53); reproduced with permission from BMJ Publishing Group Ltd.)

Figure 3

Fig. 4. Cumulative survival without non-fatal myocardial infarction (composite outcome 1; cardiac death and non-fatal myocardial infarction) among experimental (Mediterranean group) patients and control subjects in the Lyon Diet Heart Study. Cumulative survival was significantly different between groups (P=0·0001). (From de Lorgeril et al.(63); reproduced with permission.)